Rubicon Biotechnology focuses on developing innovative therapeutic technologies aimed at addressing critical health issues in cardiology, neurology, ophthalmology, and oncology. One of their primary platforms is Fv-Hsp72, which is designed to deliver heat shock protein 72 to protect cells from damage caused by hypoxic and oxidative stress, particularly in conditions such as traumatic brain injury and myocardial infarction. This technology is being advanced through collaboration with Celltheon Corporation, which provides specialized expression technologies to enhance the production of Fv-Hsp72. The goal is to create high-titer cell lines that can produce the protein in large quantities for research and clinical applications.

In addition to Fv-Hsp72, Rubicon has licensed the Modified Annexin A5 technology, which targets tumor cells to deliver immunostimulants that boost the immune response against cancer. This dual-platform approach aims to improve health outcomes by providing targeted therapies that can effectively address both acute injuries and chronic diseases like cancer. By leveraging these advanced technologies, Rubicon Biotechnology is committed to developing life-saving treatments that can significantly impact patient care and recovery.

United States

Rubicon Biotechnology is a drug development company specializing in powerful biologics for trauma and cancer, including Fv-Hsp72 for Traumatic Brain Injury. The company focuses on targeted therapies based on novel platform technologies to treat cardiovascular diseases and cancer.

Rubicon Biotechnology

Company Details